1 / 15

Pr Francois Dabis and Dr Antoine Jaquet

Antiretroviral therapy, cancer prevention and care in Africa The experience of the IeDEA West Africa Collaboration. Pr Francois Dabis and Dr Antoine Jaquet Institute of Public Health, Epidemiology & Development (ISPED), Bordeaux University.

renee
Download Presentation

Pr Francois Dabis and Dr Antoine Jaquet

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Antiretroviral therapy, cancer prevention and care in AfricaThe experience of the IeDEA West Africa Collaboration Pr Francois Dabis and Dr Antoine Jaquet Institute of Public Health, Epidemiology & Development (ISPED), Bordeaux University

  2. IeDEAInternational Epidemiologic Databases to Evaluate AIDS • International research consortium established in 2005 by the US National Institute of Allergy and Infectious Diseases (NIH) • Resource for globally diverse HIV/AIDS data • To address research questions in HIV/AIDS unanswerable by single cohorts • First round 2006-2011; Second round 2011-2016: currently year 9: July 2014 to June 2015

  3. IeDEA Regions

  4. IeDEA West Africa (WADA) • WADA: 17adult and 11 pediatric centres in 10 countries Benin, Burkina Faso, Côte d’Ivoire, Ghana, Guinea, Guinea-Bissau, Mali, Nigeria, Senegal, Togo • Coordinating Center: ISPED, Univ Bordeaux, France • Regional Office: PAC-CI, CHU Treichville, Abidjan Côte d’Ivoire

  5. WADA Objectives (1) • To measure the effectiveness of ART in HIV-infected individuals in West Africa in the long-term, and to assess factors that influence program and treatment outcomes

  6. WADA Objectives (2) • To measure the effectiveness of ART in HIV-infected individuals in West Africa in the long-term, and to assess factors that influence program and treatment outcomes • To increase the capacity for delivering ART durably in West Africa by increasing the capacity for monitoring clinical outcomes at the individual and population levels in adults and children

  7. WADA Objectives (3) • To measure the effectiveness of ART in HIV-infected individuals in West Africa in the long-term, and to assess factors that influence program and treatment outcomes • To increase the capacity for delivering ART durably in West Africa by increasing the capacity for monitoring clinical outcomes at the individual and population levels in adults and children • To document the morbidity burden in HIV-infected individuals in care in HIV programs throughout West Africa to look for prevention and care solutions

  8. WADA study design • Observational prospective multi-center cohort • Pooled database of HIV-infected adults and children data followed in reference clinics in West Africa • Additional surveys to address specific questions / specific populations • With a focus on cancer in people living with HIV

  9. Current WADA merger Retrospective and prospective cohort HIV-infectedadults on ART N= 59,941 HIV-2 or (HIV-2 and HIV-1) positive N= 4,818 HIV-exposed children N= 2,819 HIV-infected children without ART N= 1,775 HIV-infected children with ART N= 4,899

  10. Context • How routinely collected data can help addressing priority research questions in the area of HIV-related malignancies in West Africa? • No routine data collection on cancer and its risks factors available among HIV-infected patients • Sparse functional cancer registries • No national death registries and no national identification number • Need to document HIV-related malignancies and their risk factors in West Africa using appropriate approaches

  11. Studying cancer risk factors • Dedicated prevalence studies in WADA participating clinics Alcohol and tobacco use in HIV-infected patients Jaquetet al. Int J Tub Lung Dis, 2009 Jaquetet al. Addiction, 2010 • Documented the diversity of substance abuse across different countries using standardized & reproducible tools • Perspectives Enables the extension of this approach • In other IeDEA regions • Over time in the same sites to identify trends • Minimal data collection for clinical use?

  12. HIV-related malignancies (1) • Cancer of the cervix & precancerous lesions • Cancer of the cervix sufficiently frequent and eligible to an affordable preventive approach including screening and early treatment • Operational characteristics related to the screening in HIV-positive women were documented (Horo et al. BMC Public Health 2012) • Factors associated with precancerous lesions among ART-treated HIV-positive women were investigated (Jaquet et al. Plos One 2014) • Perspectives Follow-up of initially screened women to assess the incidence of new lesions as well as recurrent lesions in previously treated women Integration in routine HIV care?

  13. HIV-related malignancies (2) • How to document less common HIV-related malignancies? • Extend the WADA network to cancer referral centers HIV and cancer in referral hospitals from four West African countries • Systematic collection of HIV status in patients with a malignant conditionattending clinical wards from participating referral hospitals • Allowed the comparison of HIV seroprevalence in selected cancers known or suspected to be linked to HIV to a referent group of patients with malignant conditions unrelated to HIV • To be presented in the following session “Beyond Control of HIV: Comorbidities and Coinfections around the World” on Wednesday 16:30 (Melbourne Room 1)

  14. Conclusions • The WADA network allowed the collection of various cancer risk factors and precancerous conditions amenable to prevention strategies in West Africa • Particularly important in a context of unaffordable therapeutic approach for cancer with advances stages • Limitations • Unable to collect reliable and detailed information of invasive malignancies in HIV cohorts as morbid events • Perspective • Initiate prospective sub-cohorts of “high-risk populations” within the WADA collaboration focusing on selected types of cancers Ex: “Hepatocarcinoma among HIV/HBV co-infected cohorts”

  15. Programme PAC-CI • Acknowledgments • All patients & medical staff that participated to the cancer studies • HIV & Cancer studies coordinators & investigators • Bordeaux: E Balestre, A Sasco • Benin: J Akakpo, J Sehonou, DM Zannou • Côte d’Ivoire: A Tanon, A. Attia, SP Eholie, E. Bissagnene • Nigeria: E Oga, M Odutola, E Jedy-Agba, M Charurat, C Adebamowo • Togo: DK Ekouevi, B Goilibe • PACCI regional center for data management : TA Azani, P Coffie & colleagues • WADA PIs: E Bissagnene & F Dabis

More Related